2 results
Approved WMOCompleted
Primary objectives: - Clinical: To assess the efficacy of MPDL3280A pre-cystectomy with respect to pCRR in patients with T2-T4aN0M0 transitional cell carcinoma of the bladder- Biological: To assess the effect of 2 x 3 weekly cycles of MPDL3280A pre-…
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.